Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
CSL Behring Will Continue to Sell Helixate®FS
 

Early this month CSL Behring announced that it had reached an agreement with Bayer HealthCare LLC to continue to supply and distribute a recombinant factor VIII (rFVIII) product used to treat patients with hemophilia A. The drug is manufactured by Bayer and is sold by Bayer HealthCare Pharmaceuticals under the brand name Kogenate® FS. It is sold by CSL Behring under the brand name Helixate® FS.

 

The February 1, 2007, agreement extends the companies’ existing contract through 2017. In addition, Bayer was also granted an intellectual property license related to rFVIII. In addition, the two companies settled some outstanding litigation related to the supply of the drug. The terms of the settlement were not disclosed.

 

 “This is also a collaboration that has served the global hemophilia community through expanded distribution of our reliable Kogenate® and Helixate® line of products; reliability demonstrated by nearly two decades of clinical experience and more than 6 billion units infused,” said Dr. Gunnar Riemann, board member of Bayer HealthCare AG. 

   

“Securing the long-term supply of this life-saving therapy is significant for the patient communities we serve,” said Peter Turner, president of CSL Behring. “Under this agreement, we will have the ability to increase the supply of Helixate available for our customers. We highly value our long-term relationship with Bayer and look forward to continuing it through the next decade.”

 

Source: CSL Behring news release dated February 1, 2007